In addition, very recent meta-analysis, paradoxically, showed a significant increase in the risk of myocardial infarction and an increase in cardiovascular death of borderline significance with rosiglitazone, a member of PPAR γ agonists that is widely used as antidiabetic agent [ 49 ].
1
—
—